Cara Therapeutics, Inc. (CARA)
NASDAQ: CARA · Real-Time Price · USD
4.950
-0.200 (-3.88%)
Mar 31, 2025, 3:13 PM EDT - Market open

Company Description

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States.

The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.

It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica.

The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea.

Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Cara Therapeutics, Inc.
Cara Therapeutics logo
Country United States
Founded 2004
IPO Date Jan 31, 2014
Industry Biotechnology
Sector Healthcare
Employees 10
CEO Christopher Posner

Contact Details

Address:
400 Atlantic Street, Suite 500
Stamford, Connecticut 06901
United States
Phone 203 406 3700
Website caratherapeutics.com

Stock Details

Ticker Symbol CARA
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001346830
CUSIP Number 140755208
ISIN Number US1407552082
SIC Code 2834

Key Executives

Name Position
Christopher A. Posner President, Chief Executive Officer and Director
Ryan D. Maynard Chief Financial Officer
Scott M. Terrillion J.D. Chief Compliance Officer, General Counsel and Corporate Secretary
Matthew Murphy Manager of Investor Relations

Latest SEC Filings

Date Type Title
Mar 24, 2025 425 Filing
Mar 24, 2025 8-K Current Report
Mar 11, 2025 10-K Annual Report
Feb 14, 2025 EFFECT Notice of Effectiveness
Feb 14, 2025 424B3 Prospectus
Feb 14, 2025 S-4/A Filing
Jan 27, 2025 S-4/A Filing
Jan 21, 2025 425 Filing
Jan 21, 2025 8-K Current Report
Jan 17, 2025 425 Filing